Lipid lowering drugs.

BMJ (Clinical research ed.) ·Vol. 300 ·No. 6725 ·1990-03-10 ·Pages 667-72

O'Connor P, Feely J, Shepherd J

Abstract

暂无摘要

MeSH Terms

Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemias/drug therapy Hypolipidemic Agents/therapeutic use Nicotinic Acids/therapeutic use

Chemicals

Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypolipidemic Agents Nicotinic Acids

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

O'Connor P

Department of Pharmacology and Therapeutics, Trinity College Medical School, St James's Hospital, Dublin.

Feely J

Shepherd J

References (30)

30 references, click to expand

How LDL receptors influence cholesterol and atherosclerosis.
Sci Am. 1984 Nov;251(5):58-66 PMID: 6390676
HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
N Engl J Med. 1988 Jul 7;319(1):24-33 PMID: 3288867
Pathogenesis and management of lipoprotein disorders.
N Engl J Med. 1985 May 16;312(20):1300-10 PMID: 3887163
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Atherosclerosis. 1985 Mar;54(3):273-81 PMID: 3994783
High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men.
Br Med J (Clin Res Ed). 1986 Feb 22;292(6519):515-9 PMID: 3081149
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Am J Cardiol. 1986 Jun 27;57(16):29H-35H PMID: 3728307
Drug treatment for hypercholesterolaemia.
Q J Med. 1986 Aug;60(232):733-5 PMID: 3774956
Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.
Atherosclerosis. 1988 Jun;71(2-3):113-9 PMID: 3401284
Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect.
Br Med J (Clin Res Ed). 1985 Apr 27;290(6477):1239-43 PMID: 3921172
Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.
N Engl J Med. 1980 May 29;302(22):1219-22 PMID: 7366673
Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.
N Engl J Med. 1981 Jan 29;304(5):251-8 PMID: 7003391
Lipoproteins, cardiovascular disease, and death. The Framingham study.
Arch Intern Med. 1981 Aug;141(9):1128-31 PMID: 7259370
Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis.
Med Clin North Am. 1982 Mar;66(2):441-54 PMID: 7040846
Treatment of hypercholesterolemia.
Med Clin North Am. 1982 Mar;66(2):537-50 PMID: 7040850
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Atherosclerosis. 1982 Apr;42(2-3):229-43 PMID: 6951582
Treatment of homozygous familial hypercholesterolaemia with probucol.
S Afr Med J. 1982 Jul 3;62(1):7-11 PMID: 7089781
The plasma lipoproteins as risk factors: comparison of electrophoretic and ultracentrifugation results.
Metabolism. 1982 Aug;31(8):773-7 PMID: 6954343
Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
Atherosclerosis. 1982 Aug;44(2):211-21 PMID: 6753860
Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial.
Lancet. 1983 Sep 17;2(8351):639-42 PMID: 6136793
Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.
Circulation. 1984 Feb;69(2):313-24 PMID: 6360414
Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
JAMA. 1984 May 4;251(17):2241-6 PMID: 6368883
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
Arteriosclerosis. 1986 Nov-Dec;6(6):670-8 PMID: 3535757
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
J Am Coll Cardiol. 1986 Dec;8(6):1245-55 PMID: 3782631
Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
Drugs. 1987 Jun;33(6):539-76 PMID: 3301301
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Circulation. 1987 Sep;76(3):534-8 PMID: 3113763
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
N Engl J Med. 1987 Nov 12;317(20):1237-45 PMID: 3313041
Pharmacology of fenofibrate.
Am J Med. 1987 Nov 27;83(5B):21-5 PMID: 3318449
Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.
Am J Med. 1987 Nov 27;83(5B):26-36 PMID: 3318450
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
Am J Med. 1987 Nov 27;83(5B):50-9 PMID: 3318454
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
Atherosclerosis. 1988 Mar;70(1-2):115-21 PMID: 3281679

Article Info

Journal

BMJ (Clinical research ed.)

Abbr.

BMJ

ISSN

0959-8138

DOI

10.1136/bmj.300.6725.667

Published

1990-03-10

Pages

667-72

Language

English

Region

England

NLM ID

8900488

PMCID

PMC1662400

Subset

Corrections

CommentIn

PMID: 2112035

External Links

PubMed source DOI: 10.1136/bmj.300.6725.667 PMC Full Text

Analysis Services

Lipid lowering drugs.

Contact

WeChat Official Account